Abstract
Within the clinical trial EORTC 11001, patients were infused with (10)B-enriched borono-phenylalanine-fructose complex (BPA-fr), or borocaptate sodium (BSH) solutions, which are used as boron carriers for boron neutron capture therapy. Urine samples were periodically collected and analyzed by (10)B NMR spectroscopy. The results revealed time-dependent metabolic changes of the administered compounds. BPA-fr dissociated to the constituents BPA and fructose, and the borate group was partly cleaved from BPA. BSH was partly aggregated to a dimer form, BSSB. These observations were previously reported for cultured cells and animal models, and are confirmed here in human cancer patients.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Borohydrides / metabolism*
-
Borohydrides / urine
-
Boron Compounds / chemistry
-
Boron Compounds / metabolism*
-
Boron Compounds / urine
-
Boron Neutron Capture Therapy / methods*
-
Carcinoma, Squamous Cell / therapy
-
Clinical Trials as Topic
-
Fructose / chemistry
-
Head and Neck Neoplasms / therapy
-
Humans
-
Magnetic Resonance Spectroscopy / methods
-
Phenylalanine / analogs & derivatives*
-
Phenylalanine / chemistry
-
Phenylalanine / metabolism
-
Phenylalanine / urine
-
Sulfhydryl Compounds / metabolism*
-
Sulfhydryl Compounds / urine
-
Time Factors
Substances
-
Borohydrides
-
Boron Compounds
-
Sulfhydryl Compounds
-
mercaptoundecahydrododecaborate
-
Fructose
-
Phenylalanine
-
4-boronophenylalanine